Neuronetics is trading at $2.76, down -7.34% in pre-market; the specific reason remains unclear.
- No company-specific announcement, filing, downgrade, or other catalyst was identified for August 26, 2026.
- The latest investor-relations release was August 11, covering second-quarter results with improved revenue and margins and a narrower loss.
- Broader markets were mixed and do not clearly explain the decline.